Angiosarcomas represent a rare and highly aggressive soft tissue sarcoma subtype with a high risk for local recurrences and distant metastases ([@bib27]; [@bib1]; [@bib28]; [@bib24]; [@bib34]; [@bib12]; [@bib31]). Angiosarcomas are broadly divided into primary and secondary tumours in relation to whether a predisposing factor, for example, radiotherapy, long-standing lymphedema or chemical exposure can be identified in which case the tumours are classified as secondary angiosarcoma ([@bib33]; [@bib25]; [@bib29]; [@bib4]; [@bib18]; [@bib22]; [@bib34]; [@bib32]). About 40% of secondary angiosarcomas are estimated to develop following radiotherapy for breast cancer ([@bib19]). Even if the absolute risk of secondary angiosarcoma after radiotherapy for breast cancer is estimated to be \<0.5%, improved breast cancer survival rates imply that an increasing number of individuals are at risk of this rare complication. Altered treatment principles for breast cancer are reflected in a changing presentation of secondary angiosarcomas---from tumours that present in the upper extremity following many years of long-standing lymphedema, that is Stewart-Treves syndrome, to tumours that present after 5--10 years within the irradiated field ([@bib33]; [@bib4]; [@bib3]; [@bib6]; [@bib34]).

Morphologically, primary and secondary angiosarcomas appear indistinguishable. Molecular studies have demonstrated upregulation of *MYC* and *KDR* in secondary angiosarcomas compared with primary angiosarcomas and atypical vascular lesions ([@bib1]; [@bib24]; [@bib12]; [@bib11]; [@bib26]; [@bib17]). With the aim to delineate genetic discriminators of primary and secondary angiosarcomas and to identify key tumorigenic pathways in these tumours, we applied whole-genome expression profiling to 26 primary and 29 secondary angiosarcomas.

Materials and Methods
=====================

Sample selection and histopathological evaluation
-------------------------------------------------

Adult (\>18 years) patients with angiosarcoma were eligible for the study. Primary angiosarcomas were included irrespective of the patient\'s sex and the anatomical tumour location. Secondary angiosarcomas were defined as sarcomas located in an irradiated field that developed minimum 3 years after treatment for the primary tumour and were required to show an angiogenic histology that differed from that of the primary tumour ([@bib8]; [@bib2]; [@bib7]). All secondary angiosarcomas developed following radiotherapy for primary breast cancer. The cases were identified using the Swedish Cancer Registry, the Southern Sweden Pathology Register and the Registry of Histopathology and Cytopathology in the Netherlands (PALGA) and the patients had been treated at the Lund Sarcoma Center, Sweden (covering 1.7 million inhabitants) and at the University Medical Center in Groningen, the Netherlands (covering 1.8 million inhabitants). In total, 46 primary and 37 secondary angiosarcomas were identified from which formalin-fixed, paraffin-embedded tissue could be retrieved from 38 primary and 35 secondary angiosarcomas. Outcome data has previously been presented for the secondary angiosarcomas ([@bib34]; [@bib31]). All cases were morphologically reviewed by an experienced sarcoma pathologist (HAD) based on Hematoxylin and Eosin-stained sections and complementary immunohistochemical stainings for CD31 (Dako, Glostrup, Denmark; clone JC70A, diluted 1 : 30), CD34 (Dako, clone QBEnd-10, diluted 1 : 50) and anti-human cytokeratin (Dako, clone AE1/AE3, diluted 1 : 50).

RNA isolation and gene expression analysis
------------------------------------------

Adequate tumour material for RNA extraction was available from 26 primary and 29 secondary angiosarcomas. Clinical characteristics are described in [Table 1](#tbl1){ref-type="table"}. The tumour blocks were median 11 (2--29) and 6 (2--35) years old in the primary and the secondary angiosarcoma subsets, respectively. Biological replicates (from different tumour areas in two primary and five secondary angiosarcomas) were included. Macro-dissection of non-necrotic tumour areas was performed followed by RNA extraction of three 10-*μ*m sections using the High Pure RNA Paraffin Kit (Roche, Castle Hill, Australia) according to the manufacturer\'s instructions. Concentrations of RNA were determined using a NanoDrop Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and samples yielding sufficient RNA (350 ng) with 260/280 ratios\>1.8 were selected. Gene expression analysis was performed at the SCIBLU Genomics Centre, Lund University, Sweden. The Illumina Bead-array (HumanWG-6 v4 Expression Beadchip; Illumina, San Diego, CA) system was used according to the manufacturer\'s instructions. Expression data were uploaded and processed in the GenomeStudio software (Illumina). Data were normalised using background correction and the cubic spline method ([@bib37]). RefSeq features with a detection *P*-value⩽0.01 in at least 80% of the samples were included, leaving 14 382 features for further analysis. The data were uploaded into MeV 4.7.4 ([@bib30]) where they were log 2-transformed and median-centered across assays. Unsupervised hierarchical clustering was performed using the Pearson Correlation and average linkage clustering. All replicates clustered together, which motivated inclusion of one of the replicate signatures in the further analysis. Significance analysis for microarrays (SAM) ([@bib35]) was used to identify differentially expressed genes in primary and secondary angiosarcomas with a false discovery rate (FDR) of 0% and a fold change of minimum 2.0. Biological pathways and gene ontology (GO) terms were identified using the web-based Database for Annotation, Visualization and Integrated Discovery 6.7 (DAVID) ([@bib15]) software with a FDR⩽5%. Clinical characteristics are described in [Table 1](#tbl1){ref-type="table"}. The gene expression data can be accessed through GEO accession number GSE52664.

Validation of gene expression results using reverse transcription quantitative PCR (RT--qPCR)
---------------------------------------------------------------------------------------------

Representative primary (*n*=10) and secondary (*n*=10) angiosarcomas with stable gene expression data and sufficient biological material were selected for validation of the DASL results. Expression levels of *MYC* (Hs99999003_m1), *RET* (Hs01120027_m1) and *CDKN2C* (Hs00176227_m1) were determined using RT--qPCR. Briefly, 3 *μ*g of total RNA was reversely transcribed (Quantitect Reverse Transcription Kit, Qiagen, Hilden, Germany) and cDNA corresponding to 50 (*MYC*, *UBC*, *RPS17*) or 240 (*RET*, *CDKN2C*) ng of total RNA was used as a template in qPCR (Quantitect Probe PCR Kit, Qiagen) with predesigned hydrolysis probe assays (Taqman, Life Technologies, Applied Biosystems, Warrington, UK). The *UBC* (Hs00824723_m1) and *RPS17* (Hs02386586_g1) genes were used as endogenous reference. The cDNA pooled from two hemangioma tissue specimens served as normaliser. All samples were run in triplicate. A dilution series to verify reaction efficiency as well as no template controls were included in each run. Expression ratios were calculated by the 2^−ΔΔCT^ formula. Wilcoxon\'s rank sum test was used to compare expression ratios between primary and secondary angiosarcomas and the results were visualised using scatterplots.

Immunohistochemical expression of target proteins
-------------------------------------------------

Immunohistochemical expression was evaluated in 4-*μ*m sections from tissue microarray blocks (RET, KIT, CDKN2C) or regular tumour blocks (KDR). The antibodies used were KIT (A4502, Dilution 1 : 400, Dako), RET (MA1-26379, Dilution 1 : 25, Thermo Scientific, Waltham, MA, USA), CDKN2C (NB120-3216, Dilution 1 : 25, Novus Biologicals, Cambridge, UK) and KDR (Clone 55B11, Dilution 1 : 100, Cell Signaling, Danvers, MA, USA). The KIT staining was defined as positive or negative while the remaining stainings were graded in three-tier scales ([@bib1]). All stainings were independently scored by two investigators (ES and MN) with agreement in \>95% of the cases. Correlation between the gene expression analysis and the immunohistochemical result was evaluated using Pearson\'s product-moment correlation test. Comparison between the immunohistochemical expression patterns in primary and secondary angiosarcomas was assessed using Wilcoxon\'s rank sum test with statistical significance set at *P*\<0.05.

External validation
-------------------

To validate the 103-gene signature identified in primary *vs* secondary angiosarcomas, we applied our gene signature to the E-MEXP-3271 data set consisting of 7 primary and 18 secondary angiosarcomas of which the latter had developed following radiotherapy for breast cancer ([@bib13]). A gene expression centroid was constructed by averaging the expression values of the samples in primary and secondary angiosarcomas for each gene in order to establish a signature classifier for nearest centroid classification. A sample from the external data set was assigned to either of the two subsets based on the maximum Pearson correlation of its centroid expression to the angiosarcomas centroid values. Further, we applied the external transcriptome signature for secondary angiosarcomas ([@bib13]) to our data using supervised hierarchical clustering.

Results
=======

Target genes and key pathways
-----------------------------

Unsupervised hierarchical cluster analysis did not separate primary from secondary angiosarcomas ([Figure 1](#fig1){ref-type="fig"}). The SAM analysis, however, identified 103 genes that were significantly deregulated comparing primary and secondary angiosarcoma ([Figure 2](#fig2){ref-type="fig"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). In secondary angiosarcoma, 54 genes, including *MYC*, *KIT* and *RET,* were upregulated and 49 genes, including *CDKN2C,* were downregulated ([Table 2](#tbl2){ref-type="table"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Additional genes with fold changes \>2.0, some not previously described, were included but were not limited to, *UNC5A, CTLA4, ISLR2, ICOS, RAB17, FLT4* and *RASGRP3*. The DAVID analysis identified significant upregulation of the receptor protein tyrosine kinase pathway (EC number 2.7.10.1; FDR 4.4%, *P*\<0.01) based on overrepresentation of, for example, *RET*, *KIT* and *FLT4*.

In primary angiosarcomas, SAM analysis identified 49 upregulated genes, which included *NTSR*-1, *ANKRD1* and *CDKN2C.* No significant deregulated pathway was identified, but seven GO-terms, including cytokine receptor activity, regulation of cell size, the cell membrane and cell adhesion were enriched in primary angiosarcomas compared with secondary angiosarcomas.

RT--qPCR
--------

RT--qPCR confirmed significant (*P*\<0.005) upregulation of *MYC* and *RET* and downregulation of *CDKN2C* in secondary angiosarcomas compared with primary angiosarcomas and hemangioma ([Figure 3](#fig3){ref-type="fig"}).

Immunohistochemical profiles
----------------------------

Immunohistochemical stainings focused at key target proteins with differential expression between primary and secondary angiosarcomas. KDR was highly expressed in 36 out of 39 secondary angiosarcomas and was thus significantly over-expressed secondary angiosarcomas ([Figure 4](#fig4){ref-type="fig"}). The Pearson\'s product-moment correlation test showed significant correlation between the immunohistochemical staining and the gene expression profile for KDR (*r*=0.6; *P*=3 × 10^−7^). Also KIT expression showed significant correlation between the immunostaining and the gene expression profile (*r*=0.33; *P*=0.01), but did not reveal differential immunostaining between primary and secondary angiosarcomas. For RET and CDKN2C immunostaining and gene expression, data were not significantly correlated, which suggest other or more complex mechanisms of action than protein or gene overexpression.

External validation
-------------------

The 103-gene signature identified between primary and secondary angiosarcomas in our series was applied to the sample set used by [@bib13] (accession number E-MEXP-3271) . The 103-signature achieved separation of the 25 tumours of the external data set into primary and secondary angiosarcoma ([Figure 5](#fig5){ref-type="fig"}). The more limited 53-gene signature suggested by [@bib13] was conversely applied to our data set. However, only 29 genes were shared and they did not allow for separate clustering between primary and secondary angiosarcomas (data not shown).

Discussion
==========

Primary and secondary angiosarcomas in our series show expression profiles with 103 significantly deregulated genes ([Figure 2](#fig2){ref-type="fig"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). Key target genes between the subsets included *MYC*, *KIT, RET* and *CDKN2C.* Whereas *MYC* and *KIT* have been linked to secondary angiosarcoma, involvement of *RET* and *CDKN2C* has not previously been described in this tumour type. Deregulation of *MYC, RET* and *CDKN2C* was validated using RT--qPCR and immunohistochemistry. Additional genes, not previously described in secondary angiosarcomas, included *UNC5A, CTLA4, ISLR2, ICOS, RAB17* and *RASGRP3. FLT4*, which has been previously been described ([@bib12]) was upregulated with a fold change of 2.0 in our series.

Secondary angiosarcomas showed upregulation of RET signalling and consequently downregulation of the down-stream target CDKN2C ([Table 2](#tbl2){ref-type="table"}). Activation of RET linked to mutations in *RET* and protein overexpression has been reported at high frequencies in radiation-associated thyroid cancer ([@bib5]; [@bib9]). Functional studies also support synergistic effects from *RET* activation and *CDKN2C* inactivation ([@bib10]; [@bib16]; [@bib36]; [@bib21]). N-MYC represents a down-stream target of RET and a key step in CDKN2C downregulation. In multiple endocrine neoplasia type 2 and in medullary thyroid cancer, *N-MYC* induction has been identified as a key tumorigenic step associated with downregulation of *CDKN2C* ([@bib21]). Involvement of MYC, RET and FLT4 has been reported in secondary angiosarcomas as well as in other radiation-induced tumours ([@bib1]; [@bib24]; [@bib12]; [@bib11]; [@bib13]; [@bib26]; [@bib17]). Our findings of *MYC, RET* and *FLT4* upregulation and *CDKN2C* downregulation thus suggest shared tumorigenic mechanisms between different types of radiation-induced tumours.

We found a strong immunohistochemical expression for KDR ([Figure 4](#fig4){ref-type="fig"}) in 36 out of 39 secondary angiosarcomas. The upregulation at the protein level was significantly correlated to increased gene expression levels. Our results are consistent with previous reports of upregulation of vascular-specific receptor tyrosine kinases, for example, *TIE1, KDR* and *FLT1* in angiosarcoma ([@bib1]). *KDR* regulates endothelial cell survival, proliferation, migration and vascular formation during embryonic development and tumorigenesis ([@bib20]). Activating mutations in *KDR* have been demonstrated in 10% of angiosarcomas and have been linked to tumour localisation in the breast ([@bib1]).

The 103-gene signature achieved reproducible clustering of primary and secondary angiosarcomas in an external data set ([Figure 5](#fig5){ref-type="fig"}). The ability of our signature to cluster independent angiosarcomas suggests a stable and reproducible performance of our results.

Angiosarcomas are aggressive malignant tumours that are generally resistant to chemotherapy and represent a tumour subset where novel therapeutic approaches are needed. Identification of RET signalling as a key feature in secondary angiosarcomas suggests that treatment with RET-kinase-inhibitors may be relevant to evaluate in this tumour subset. Although no specific RET-inhibitor is available, several multi-kinase-inhibitors such as sorafenib, vandetanib and sunitinib, inhibit the RET kinase and cause tumour growth arrest in preclinical models ([@bib14]). In phase I--II clinical trials, RET inhibitors have shown limited effects in mixed series of soft tissue sarcomas ([@bib23]). Previous trials have not selected patients based on primary *vs* secondary angiosarcomas or RET status; a response rate of 14% has been reported in angiosarcomas ([@bib23]). Our data suggest that further studies of RET inhibitors should consider secondary angiosarcoma and evaluate clinical benefit in relation to RET status.
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###### 

Click here for additional data file.

![**Unsupervised hierarchical clustering of the 28 primary (green) and 34 secondary (blue) angiosarcomas (X-axis).** Samples with similar gene expression profiles cluster together. The full heat map is available upon request from the corresponding author.](bjc2014359f1){#fig1}

![**Heat map (SAM analysis) of the 103 genes (Y-axis) expressed at significantly different levels between 28 primary (green) and 24 secondary (blue) angiosarcomas.** Samples with similar gene expression profiles cluster together on the X-axis. Upregulated expression is marked with red, and downregulated with green and black reflects no difference in expression levels.](bjc2014359f2){#fig2}

![**Scatterplots demonstrating the RT--qPCR expression ratios (Y-axis) in primary and secondary angiosarcomas (X-axis) in relation to the pooled reference genes.** In secondary angiosarcoma upregulation affects (**A**) MYC and (**B**) RET, whereas downregulation is demonstrated for (**C**) CDKN2C.](bjc2014359f3){#fig3}

![**Immunohistochemical staining for KDR** Immunohistochemical staining for KDR in (**A**) a primary angiosarcoma with low expression, \<20% of the cells positive; (**B**) secondary angiosarcoma with intermediate expression, ⩾20% but \<75% (**C**) secondary angiosarcoma with high expression, immunoreactivity\>75% of the cells. Grading was performed according to [@bib1]. The expression intensities were determined in the areas with highest staining intensity.](bjc2014359f4){#fig4}

![**Heat map and hierarchical clustering of our 103-gene signature applied to the external data set E-MEXP-3271 ([@bib13]).** Distinct separation is obtained between primary (green) and secondary (blue) angiosarcomas. Samples with similar gene expression profiles cluster together; red: upregualted expression, green: downregulated expression, black: no difference in expression levels.](bjc2014359f5){#fig5}

###### Summary of clinical characteristics

                                                        **Primary angiosarcomas**   **Secondary angiosarcomas**
  ----------------------------------------------------- --------------------------- -----------------------------
  Number of patients                                    26                          29
  Age at diagnosis (median, range)                      68 (3--91)                  68 (50--90)
  Sex (f/m)                                             16/10                       29/0
  **Location**                                                                      
  Head and neck                                         6                           ---
  Upper extremity                                       3                           2
  Thoracical wall                                       5                           27
  Lower extremity                                       4                           ---
  Other locations                                       8                           ---
  Median years between breast cancer and angiosarcoma   ---                         8 (4--20)

Abbreviations: f=female; m=male.

###### Selected deregulated genes with their respective fold changes

  **Gene**   **Definition**                                                                        **Chromosome**   **Fold change**
  ---------- ------------------------------------------------------------------------------------ ---------------- -----------------
  *MYC*      *V-myc* myelocytomatosis viral oncogene homologue                                           8                3.7
  *RET*      *Ret* proto-oncogene (*RET-ELE1, MEN2A, MEN2B, RET51*)                                      10               3.0
  *KIT*      *V-kit* Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue (*CD117, C-KIT*)          4                2.1
  *FLT4*     Fms-related tyrosine kinase 4 (FLT4)                                                        5                2.0
  *CDKN2C*   Cyclin-dependent kinase inhibitor 2C (*INK4C, p18*)                                         1                0.5

Abbreviation: MEN2=multiple endocrine neoplasia type 2.
